Insider Transactions in Q1 2023 at Laboratory Corp Of America Holdings (LH)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
3,897
-36.82%
|
$876,825
$225.81 P/Share
|
|
Mar 30
2023
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,646
-28.45%
|
$4,176,704
$224.7 P/Share
|
|
Mar 30
2023
|
Adam H Schechter President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
42,353
+39.26%
|
-
|
|
Mar 30
2023
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,179
-10.94%
|
$1,160,096
$224.7 P/Share
|
|
Mar 30
2023
|
Glenn A Eisenberg Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
11,715
+19.83%
|
-
|
|
Mar 30
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,886
-18.23%
|
$646,464
$224.7 P/Share
|
|
Mar 30
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,763
+29.93%
|
-
|
|
Mar 30
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,866
-21.31%
|
$641,984
$224.7 P/Share
|
|
Mar 30
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Grant, award, or other acquisition
|
Direct |
6,763
+33.46%
|
-
|
|
Mar 30
2023
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,799
-7.29%
|
$402,976
$224.7 P/Share
|
|
Mar 30
2023
|
Lance Berberian EVP, CIO & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
4,509
+15.45%
|
-
|
|
Mar 30
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,990
-12.9%
|
$669,760
$224.7 P/Share
|
|
Mar 30
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
6,763
+22.59%
|
-
|
|
Mar 30
2023
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,164
-21.78%
|
$260,736
$224.7 P/Share
|
|
Mar 30
2023
|
Judith C Seltz EVP, CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
3,381
+38.75%
|
-
|
|
Mar 30
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,269
-25.88%
|
$284,256
$224.7 P/Share
|
|
Mar 30
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,234
+39.74%
|
-
|
|
Mar 30
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,371
-14.97%
|
$307,104
$224.7 P/Share
|
|
Mar 30
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,609
+28.26%
|
-
|
|
Mar 30
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
526
-13.29%
|
$117,824
$224.7 P/Share
|
|
Mar 30
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,798
+31.24%
|
-
|
|
Mar 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-18.31%
|
$89,386
$239.46 P/Share
|
|
Mar 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,340
+39.61%
|
-
|
|
Feb 21
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Open market or private sale
|
Direct |
8,000
-46.87%
|
$2,000,000
$250.58 P/Share
|
|
Feb 21
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+14.95%
|
$546,000
$182.51 P/Share
|
|
Feb 14
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
309
-4.42%
|
$76,323
$247.63 P/Share
|
|
Feb 13
2023
|
Jean Luc Belingard Director |
SELL
Payment of exercise price or tax liability
|
Direct |
75
-0.44%
|
$18,600
$248.13 P/Share
|
|
Feb 13
2023
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-0.42%
|
$21,080
$248.13 P/Share
|
|
Feb 13
2023
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,170
-4.8%
|
$290,160
$248.13 P/Share
|
|
Feb 13
2023
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
195
-0.54%
|
$48,360
$248.13 P/Share
|
|
Feb 13
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
142
-1.0%
|
$35,216
$248.13 P/Share
|
|
Feb 13
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
124
-0.75%
|
$30,752
$248.13 P/Share
|
|
Feb 13
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-1.39%
|
$19,344
$248.13 P/Share
|
|
Feb 13
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
54
-7.13%
|
$13,392
$248.13 P/Share
|
|
Feb 13
2023
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
69
-3.39%
|
$17,112
$248.13 P/Share
|
|
Feb 13
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
114
-1.6%
|
$28,272
$248.13 P/Share
|
|
Feb 13
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
38
-1.73%
|
$9,424
$248.13 P/Share
|
|
Feb 11
2023
|
Jean Luc Belingard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+4.18%
|
-
|
|
Feb 11
2023
|
Kerrii B Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+3.53%
|
-
|
|
Feb 11
2023
|
Garheng Kong Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+6.35%
|
-
|
|
Feb 11
2023
|
Dwight Gary Gilliland Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+8.72%
|
-
|
|
Feb 11
2023
|
Jeffrey A. Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+21.73%
|
-
|
|
Feb 11
2023
|
Kathryn E Wengel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+35.55%
|
-
|
|
Feb 11
2023
|
Richelle P Parham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+8.91%
|
-
|
|
Feb 11
2023
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+6.32%
|
-
|
|
Feb 11
2023
|
R Sanders Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+9.37%
|
-
|
|
Feb 11
2023
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
290
+1.41%
|
-
|
|
Feb 11
2023
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,656
+9.83%
|
-
|
|
Feb 11
2023
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
723
+1.98%
|
-
|
|
Feb 11
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
483
+3.29%
|
-
|